2026 Southern Hemisphere Influenza Vaccine

The Defense Logistics Agency- Troop Support is seeking sources capable of providing Southern Hemisphere Influenza Vaccine for 2026 season. Shall be trivalent vaccine, licensed by the FDA, intended for active immunization for the prevention of influenzas for the Southern Hemisphere. Shall meet the minimum formula for the influenza vaccine as determined by the FDA’s Vaccines and Related Biological Products Advisory Committee. Shall be pre-measured 0.5ML dose, each dose shall be pre-filled in a commercially available syringe for intramuscular administration in healthy individuals aged 6 months and older. Shall be free of thimerosal or other preservatives. Shall be shipped refrigerated between 2° and 8° C. The vaccine must not be frozen. Shall be one package containing 10 pre-filled syringes as the unit of issue. Product shall be both FDA Approved and ACIP Recommendation.

DLA Troop Support has an annual estimated requirement for Southern Hemisphere Influenza Vaccine of 60,000 doses for the 2026 season. However, the quantity may increase or decrease as the Services requirements change. The vaccine shall be delivered to the Defense Distribution Center (DDC) in Susquehanna, PA, and the desirable delivery time is mid-March 2026.

This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to the RFI. All submitted information shall remain with the U.S. Government and will not be returned.

*** Currently Marketed Southern Hemisphere Influenza***

If your firm currently markets Southern Hemisphere Influenza Vaccine, please provide information with respects to the following:

1. Place of Manufacture


2. Estimated Annual Capacity


3. FDA Registration information


4. Product Name and description including description of any special features


5. Current unit sales price


6. Estimated inventory level and storage requirements


7. Delivery days for this item and earliest product available time


8. Capacity for surge and sustainment requirement


9. Country of origin for API


10. Do you have any authorized distributor for this item in the U.S.? If so, please provide the name of the authorized distributor(s).

***New Product Under Development***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture product described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.

Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Southern Hemisphere Influenza Vaccine for 2025 season. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.

Your response to this RFI may be submitted electronically in PDF format and emailed to Contracting Specialist Rosbert.Jones@dla.mil.